Noteworthy Monday Option Activity: WULF, ZBIO, LEU

Zenas Biopharma (ZBIO) saw 1,848 option contracts trade (≈184,800 underlying shares), equal to about 52.4% of its one‑month average daily volume (352,605 shares); notable activity was in the Jan 16, 2026 $17.50 call with 487 contracts (≈48,700 shares). Centrus Energy (LEU) recorded 4,585 option contracts (≈458,500 underlying shares), about 50.9% of its one‑month ADV (900,635 shares), led by 249 contracts (≈24,900 shares) in the Jan 16, 2026 $280 call. The concentrated call flows and high options-to-ADV ratios suggest sizable directional positioning or hedging in both names but do not by themselves indicate fundamentals changes.

Analysis

Market structure: The outsized Jan‑2026 call flow in LEU ($280 strike) and ZBIO ($17.50) — each representing ~50% of one‑day average volume — signals concentrated directional exposure from allocators willing to hold >12‑month duration. Winners: long equity holders of LEU and select uranium suppliers (and option sellers collecting premium). Losers: short gamma market‑makers during squeezes and miners with no enrichment capability if contract repricing favors Centrus.

Risk assessment: Tail risks include failed biotech readouts or FDA setbacks for ZBIO and regulatory/geopolitical shifts for LEU (e.g., US/IAEA export controls or cancellation of enrichment contracts); each could erase >50% of option value. Immediate (days): higher intraday IV and potential squeezes; short‑term (weeks–months): position unwinds drive volatility; long‑term (to Jan‑2026): fundamentals (uranium spot, trial outcomes) dominate. Hidden dependency: much flow may be spreads/structured product hedges, not plain directional buys — don’t assume pure conviction.

Trade implications: Favor asymmetric defined‑risk optionality. For LEU, buy Jan‑2026 call spreads to capture upside while avoiding full IV exposure; for ZBIO, limit exposure to small speculative call spreads or buy‑writes if announced catalysts exist within 6–9 months. If IV gaps >30% versus 90‑day average, opportunistically sell short‑dated call credit spreads to harvest mean reversion; size trades 0.5–2% portfolio each with strict stop 30% adverse move.

Contrarian angles: The market likely overinterprets flow as pure bullish conviction — a large block could be delta‑hedged institutional activity or conversion trades that will not move fundamentals. Low float/small cap names amplify moves; implied volatility may be overpriced relative to 12‑month realized volatility once short‑term catalysts pass. Unintended consequence: buyers push IV higher, then poor entry = permanent premium loss if no binary outcome by mid‑2025.

Key Decisions for Investors

• Establish a 1–2% long position in Centrus Energy (LEU) equity and simultaneously buy a Jan‑16‑2026 $280/$340 call spread (approx. 1:1 notional) sized 0.5–1% portfolio to cap downside; add to equity if LEU announces a DOE/contract win within 90 days.
• Initiate a speculative 0.5% position in Zenas Biopharma (ZBIO) via Jan‑16‑2026 $17.50/$27.50 call spread (defined risk capped at premium); cut at 30% loss or exit within 90 days after any negative FDA/trial update.
• If implied volatility for LEU rises >30% above its 90‑day average, sell 30–60 day call credit spreads (e.g., 5–10% OTM) sized 0.5% portfolio, close at 50% premium capture or if underlying moves against by 20% intraday.
• Pair trade: go long LEU (1% exposure) and short CCJ (Cameco, 0.5% exposure) dollar‑neutral to express enrichment margin outperformance vs miners; reassess at next uranium spot move >±20% or on DOE/IAEA policy announcements within 6–12 months.